Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ann Hanham Insider Profile
4 Followers
Ann Hanham, Director at Endocyte, holds 46.62K shares in SCYNEXIS (Ticker: SCYX), holds 7.30K shares in HTG Molecular Diagnostics (Ticker: HTGMQ), holds 2.25K shares in Endocyte (Ticker: ECYT).
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-29.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Ann Hanham holds in companies
Most Profitable Insider Trade
The most profitable trade made by Ann Hanham
Ann Hanham's Trading History
Endocyte
May 05, 2017
―
Uninformative Buy
―
$53.98K
HTG Molecular Diagnostics
Aug 16, 2019
Director
Uninformative Buy
―
$87.65
SCYNEXIS
Jun 21, 2024
Director
Uninformative Buy
―
$55.48K
Gyre Therapeutics
―
Director
―
$9.15M
Biomimetic Therapeutics
―
―
―
―
List of latest transactions for each holding click on a transaction to see Ann Hanham's performance on stock
You May Also Like
Ann Hanham insider profile FAQ
What is the percentage of profitable transactions made by Ann Hanham?
The percentage of profitable transactions made by Ann Hanham is 0%.
What is the average return per transaction made by Ann Hanham?
The average return per transaction made by Ann Hanham is -29.10%.
What stocks does Ann Hanham hold?
Ann Hanham holds: ECYT, HTGMQ, SCYX, GYRE, BMTI stocks.
What was Ann Hanham’s latest transaction?
Ann Hanham latest transaction was an Uninformative Buy of ―.
What was Ann Hanham's most profitable transaction?
Ann Hanham’s most profitable transaction was an Informative Buy of SCYX stock on December 23, 2020. The return on the trade was -4.20%.
What is Ann Hanham's role in Endocyte?
Ann Hanham's role in Endocyte is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.